MARKET

NMRA

NMRA

Neumora Therapeutics Inc
NASDAQ
1.660
-0.130
-7.26%
After Hours: 1.650 -0.01 -0.60% 18:49 01/02 EST
OPEN
1.810
PREV CLOSE
1.790
HIGH
1.824
LOW
1.570
VOLUME
1.98M
TURNOVER
--
52 WEEK HIGH
11.51
52 WEEK LOW
0.6110
MARKET CAP
282.10M
P/E (TTM)
-1.1345
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NMRA last week (1222-1226)?
Weekly Report · 12/29/2025 09:25
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/23/2025 12:05
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/23/2025 10:16
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers
NASDAQ · 12/23/2025 04:49
Weekly Report: what happened at NMRA last week (1215-1219)?
Weekly Report · 12/22/2025 09:25
Weekly Report: what happened at NMRA last week (1208-1212)?
Weekly Report · 12/15/2025 09:27
Weekly Report: what happened at NMRA last week (1201-1205)?
Weekly Report · 12/08/2025 09:27
Promising Penny Stocks To Watch In December 2025
Simply Wall St · 12/02/2025 11:05
More
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Webull offers Neumora Therapeutics Inc stock information, including NASDAQ: NMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NMRA stock methods without spending real money on the virtual paper trading platform.